Use of decision analysis in modeling the cost-effectiveness of oral vs SC sumatriptan

Vijay N. Joish, Edward P. Armstrong

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Sumatriptan products have been shown to be effective agents in treating migraine headaches. This month's column presents a cost-effectiveness analysis of two different formulations of sumatriptan using a decision-tree approach. The analysis introduces a new concept, rank-order stability analysis (ROSA), in assessing the sensitivity of a decision-tree model. The ROSA showed that the results of the cost-effectiveness analysis were elastic to variation in the primary clinical efficacy measure. However, because the incremental cost-effectiveness ratio was not large, most health care organizations will likely want to make both sumatriptan products available.

Original languageEnglish (US)
Pages (from-to)532-539
Number of pages8
JournalFormulary
Volume35
Issue number6
StatePublished - Jun 1 2000

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Use of decision analysis in modeling the cost-effectiveness of oral vs SC sumatriptan'. Together they form a unique fingerprint.

  • Cite this